RT Journal Article
SR Electronic
T1 Caffeine-potentiated Chemotherapy for Metastatic Carcinoma and Lymphoma of Bone and Soft Tissue
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2399
OP 2405
VO 25
IS 3C
A1 HAYASHI, MASAYUKI
A1 TSUCHIYA, HIROYUKI
A1 YAMAMOTO, NORIO
A1 KARITA, MICHIAKI
A1 SHIRAI, TOSHIHARU
A1 NISHIDA, HIDEJI
A1 TAKEUCHI, AKIHIKO
A1 TOMITA, KATSURO
YR 2005
UL http://ar.iiarjournals.org/content/25/3C/2399.abstract
AB Background: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas. In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy. Patients and Methods: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy. Results: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer. Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients. Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up. Conclusion: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.